Literature DB >> 29752444

Kappa-opioid antagonists as stress resilience medications for the treatment of alcohol use disorders.

Charles Chavkin1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29752444      PMCID： PMC6046055          DOI： 10.1038/s41386-018-0046-4

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN： 0893-133X            Impact factor:   7.853


× No keyword cloud information.
  6 in total

Review 1.  Dynorphin, Dysphoria, and Dependence: the Stress of Addiction.

Authors:  Charles Chavkin; George F Koob
Journal:  Neuropsychopharmacology       Date:  2016-01       Impact factor: 7.853

2.  Preclinical evaluation of the kappa-opioid receptor antagonist CERC-501 as a candidate therapeutic for alcohol use disorders.

Authors:  E Domi; E Barbier; E Augier; G Augier; D Gehlert; R Barchiesi; A Thorsell; L Holm; M Heilig
Journal:  Neuropsychopharmacology       Date:  2018-02-05       Impact factor: 7.853

3.  Opioid Modulation With Buprenorphine/Samidorphan as Adjunctive Treatment for Inadequate Response to Antidepressants: A Randomized Double-Blind Placebo-Controlled Trial.

Authors:  Maurizio Fava; Asli Memisoglu; Michael E Thase; J Alexander Bodkin; Madhukar H Trivedi; Marc de Somer; Yangchun Du; Richard Leigh-Pemberton; Lauren DiPetrillo; Bernard Silverman; Elliot Ehrich
Journal:  Am J Psychiatry       Date:  2016-02-12       Impact factor: 18.112

Review 4.  Development of κ opioid receptor antagonists.

Authors:  F Ivy Carroll; William A Carlezon
Journal:  J Med Chem       Date:  2013-02-14       Impact factor: 7.446

5.  Constitutive activation of kappa opioid receptors at ventral tegmental area inhibitory synapses following acute stress.

Authors:  Abigail M Polter; Kelsey Barcomb; Rudy W Chen; Paige M Dingess; Nicholas M Graziane; Travis E Brown; Julie A Kauer
Journal:  Elife       Date:  2017-04-12       Impact factor: 8.140

6.  Peroxiredoxin 6 mediates Gαi protein-coupled receptor inactivation by cJun kinase.

Authors:  Selena S Schattauer; Benjamin B Land; Kathryn L Reichard; Antony D Abraham; Lauren M Burgeno; Jamie R Kuhar; Paul E M Phillips; Shao En Ong; Charles Chavkin
Journal:  Nat Commun       Date:  2017-09-29       Impact factor: 14.919
  6 in total
  2 in total

Review 1.  Five Decades of Research on Opioid Peptides: Current Knowledge and Unanswered Questions.

Authors:  Lloyd D Fricker; Elyssa B Margolis; Ivone Gomes; Lakshmi A Devi
Journal:  Mol Pharmacol       Date:  2020-06-02       Impact factor: 4.436

2.  OREX-1019: A Novel Treatment of Opioid Use Disorder and Relapse Prevention.

Authors:  David R Maguire; Lisa R Gerak; Gerta Cami-Kobeci; Stephen M Husbands; Charles P France; Barbara Belli; Peter Flynn
Journal:  J Pharmacol Exp Ther       Date:  2019-11-20       Impact factor: 4.030
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.